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Abstract
Background: N-acetyl cysteine (NAC) is a glutathione precursor that has been shown to have antidepressant
efficacy in a placebo-controlled trial. The current study aimed to investigate the maintenance effects of NAC
following eight weeks of open-label treatment for bipolar disorder.
Method: The efficacy of a double blind randomized placebo controlled trial of 2 g/day NAC as adjunct
maintenance treatment for bipolar disorder was examined. Participants (n = 149) had a Montgomery Asberg
Depression Rating Score of ≥12 at trial entry and, after eight weeks of open-label NAC treatment, were randomized
to adjunctive NAC or placebo, in addition to treatment as usual. Participants (primarily outpatients) were recruited
through public and private services and through newspaper advertisements. Time to intervention for a mood
episode was the primary endpoint of the study, and changes in mood symptoms, functionality and quality of life
measures were secondary outcomes.
Results: There was a substantial decrease in symptoms during the eight-week open-label NAC treatment phase.
During the subsequent double-blind phase, there was minimal further change in outcome measures with scores
remaining low. Consequently, from this low plateau, between-group differences did not emerge on recurrence,
clinical functioning or quality of life measures.
Conclusions: There were no significant between-group differences in recurrence or symptomatic outcomes during
the maintenance phase of the trial; however, these findings may be confounded by limitations.
Trial Registration: The trial was registered with the Australian New Zealand Clinical Trials Registry
(ACTRN12607000074493).
Keywords: N-acetyl cysteine, depression, bipolar disorder, maintenance, mania, oxidative
Background
Bipolar disorder is a recurrent illness with the vast
majority of individuals experiencing relapses throughout
their lives. The prevention of further episodes is of criti-
cal importance to individuals with the disorder, as
recurrent episodes can result in hospitalization, suicide
and loss of functionality. There appears to be an active
process of neuroprogression associated with acute
episodes of illness [1]. Maintenance of well-being is,
therefore, of paramount importance [2]. Existing agents
are imperfect, as many have limitations in terms of
either efficacy or tolerability for long-term treatment.
Lithium is the mainstay of prophylaxis in bipolar disor-
der although it is more effective in preventing manic
relapses than depression [3] though recent data suggest
that it is more effective in relapse prevention than
valproate [4]. Interestingly, lithium is more effective in
preventing manic relapses as opposed to depression
whereas lamotrigine is more effective in the prevention
of depressive episodes [3]. Atypical antipsychotics also
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appear to have maintenance properties, although all
except quetiapine are less effective in depression than
mania. Given the limitations of these agents, polyphar-
macy is the routine rather than the exception [5] and
most have significant tolerability issues that require rou-
tine safety monitoring [6]. In this context there are pre-
liminary data from preclinical studies that N-acetyl
cysteine (NAC) might prevent lithium-induced renal
dysfunction in animal models. This makes it an attrac-
tive adjunct therapy both because of its potential clinical
benefits and the reduction of iatrogenic adverse effects
[7].
This is particularly interesting because it is consistent
with evidence of dysregulated redox biology in bipolar
disorder. Data supporting this comes from five main
areas; i) evidence of dysregulated oxidative defenses, ii)
effects of oxidative stress on cellular constituents (parti-
cularly lipids, proteins and nuclear and mitochondrial
DNA), iii) concordant structural evidence of neuropro-
gressive processes, iv) studies showing that established
bipolar disorder treatments have significant influences on
oxidative processes, and v) association studies of poly-
morphisms of key genes in the glutathione pathway [8].
In particular, glutathione, which is the principal endogen-
ous antioxidant in the brain, is vulnerable to depletion,
and is substantially reduced in bipolar disorder [9]. NAC
provides L-cysteine, the rate limiting factor in glutathione
synthesis, and thereby increases central and peripheral
glutathione [10]. Additionally, NAC modulates gluta-
mate, has anti-inflammatory properties and enhances
neurogenesis and mitochondrial function [11].
Given this context, the aim of this study was to investi-
gate the efficacy of adjunctive NAC, in addition to treat-
ment as usual, in the maintenance treatment of bipolar
depression in a double-blind randomized multi-center
placebo-controlled trial. Time to intervention for a mood
episode was the primary outcome measure. Secondary
outcome measures included changes in mood symptoms,
functioning and quality of life (QoL). It was hypothesized
that NAC would reduce the recurrence of episodes in the
maintenance phase of the disorder.
Methods
This maintenance study included participants screened
for the presence of depression at trial entry (beginning of
the open-label phase) [12]. All participants received 2
grams of NAC (1 gram twice daily) for eight weeks and
were subsequently randomized to continued NAC treat-
ment or placebo in a double blind design for a further 24
weeks. The assessment schedule is shown in Additional
File 1. In addition to the clinical interviews, some partici-
pants provided blood samples for peripheral analysis of
oxidative stress markers and a sub-group was involved in
a magnetic resonance spectroscopy study (data presented
elsewhere). In order to reduce enrichment bias, response
to NAC in the open label phase was not an inclusion cri-
terion, and all participants proceeded to the randomized
phase (week 8 to week 32). Methodological details and
data from the open-label phase of the study are presented
elsewhere [13]. All participants remained on treatment as
usual for the duration of the trial. This included any
pharmacological or psychological intervention (stable for
at least one month as per the inclusion criteria). In order
to capture the diversity of treatment settings and enhance
generalizability, potential participants were recruited
through a variety of avenues, including the participants’
case clinicians, newspaper advertisement, flyers in public
areas (including flyers placed at shopping centers and
pathology collection centers) and web-based advertise-
ments on bipolar disorder-relevant websites, as well as
referral from private clinicians including family physi-
cians and specialists. The trial was approved by relevant
research and ethics committees (Barwon Health, Bendigo
Health and the University of Melbourne, in Victoria,
Australia; Royal North Shore Hospital, Sydney, Australia,
and Porto Allegre, Brazil) and was conducted in accor-
dance with the Helsinki Declaration as revised in 1989. A
preliminary interview was conducted with potential parti-
cipants to obtain written informed consent and assess
inclusion and exclusion criteria, following which the trial
proper commenced.
Individuals who had given written consent were
assigned, using computer-generated block randomization
(in blocks of four) [14], to treatment with NAC or placebo
in addition to treatment as usual, in a double-blind fash-
ion. The nature and dose of the primary therapy was mon-
itored. The person generating the randomization schedule
was not involved in any aspect of participant interview or
data analysis. The investigators, clinicians and statisticians
were blind to treatment allocation. The study was regis-
tered with the Australian and New Zealand Clinical Trials
Registry (registration # 12607000074493). The trial was
completed between 2007 and 2010.
NAC was acquired from Zambon Fine Chemicals,
Bresso, Italy. Purity was 99.8% as determined by high per-
formance liquid chromatography. Encapsulation of both
the NAC and the identical placebo capsules was done by
DFC Thompson, Sydney, Australia. Study medication
was sealed in identical bottles, labeled as trial medication,
and both dispensed and returned by the pharmacy, so
that the investigators were not exposed to the contents of
the bottles. It is important to note that NAC has a char-
acteristic odor and so to reduce the risk of unblinding on
transition to the double blind phase, placebo capsules
were dusted with microgram amounts of NAC to capture
the distinct odor. Participants additionally were seen
separately, minimizing the opportunity to compare
experiences.
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Inclusion and Exclusion Criteria
To be eligible for the trial, participants were required to
meet DSM-IV criteria for bipolar I-, bipolar II- or bipolar
NOS-disorder, to have current symptoms of depression,
with a Montgomery Asberg Depression Rating Scale
(MADRS) score of ≥12 at entry into the study, have the
capacity to consent to the study and comply with study
procedures, be using effective contraception if female,
sexually active and of childbearing age and have been on
stable therapy for at least four weeks prior to randomiza-
tion. Participants were not, however, required to be tak-
ing medication at the time of recruitment. Exclusion
criteria included individuals with a known or suspected
clinically relevant acute systemic medical disorder,
elderly people with respiratory insufficiency, women who
were pregnant or lactating, participants taking more than
500 mg of NAC/day, 200 ug of selenium/day or 500 IU
of Vitamin E/day, or who have had an anaphylactic reac-
tion to NAC, or any component of the preparation, or
who were assessed as being unable to comply with either
the requirements of informed consent or the treatment
protocol. Withdrawal criteria included individuals who
ceased taking their trial medication for seven consecutive
days or who ceased effective contraception or became
pregnant. Dose changes to existing medications (either
increases or decreases in dose), or addition or removal of
an agent were noted and participants were allowed to
continue with the trial. Additionally, participants were
withdrawn from the study if they withdrew consent, or
developed adverse events that were deemed to require
withdrawal from the study.
Measurements
The participants were assessed at the commencement of
the open-label phase using the Mini International Neurop-
sychiatric Interview Plus (MINI-Plus) [15]. Time to any
intervention for mood symptoms was the primary out-
come measure of the study. The specified interventions
included initiation of a new medication, psychotherapy,
hospitalization or electroconvulsive therapy, initiation of
emergency/unscheduled medical contacts for mood symp-
toms or discontinuation or dose adjustment of a current
agent. To be considered an ‘event’, participants had to
experience one of the interventions directly in relation to
the presence of a new mood episode. Meeting time to
intervention criteria was not in itself a reason for trial dis-
continuation, and such individuals, who consented, con-
tinued to be monitored, although only the first such event
was used for analysis of the primary outcome. Change in
the clinical status of the participants was further assessed
using the MADRS [16], Bipolar Depression Rating Scale
(BDRS) [17], Young Mania Rating Scale (YMRS) [18],
Clinical Global Impression (CGI) improvement and sever-
ity scales [19], CGI modified for substance use [20] and
bipolar disorder (CGI BP) [21], Patient Global Impression
(PGI) [22], Global Assessment of Functioning Scale (GAF)
[23], Social and Occupational Functioning Assessment
Scale (SOFAS) [24], Streamed Longitudinal Interview
Clinical Evaluation from the Longitudinal Interview Fol-
low-up Evaluation (SLICE/LIFE) [25] and Range of
Impaired Functioning Tool (LIFE RIFT) [26], and the
Quality of Life Enjoyment and Satisfaction Questionnaire
(Q-LES-Q) [27]. Adherence was monitored by an indepen-
dent pharmacist, using pill counts of returned clinical trial
material. Rating scales were repeated every two weeks for
the first four weeks, thereafter monthly or on the day of
study termination if the participant withdrew prior to the
final scheduled visit [see Additional File 1]. Adverse events
were tabulated.
Statistical analysis
The last visit of the open-label phase (week 8) served as
the baseline for the maintenance phase of the trial and
the endpoint corresponded to the assessment at week 32.
All randomized participants who had at least one post-
baseline assessment were included in the analysis. Analy-
sis was performed by a consultant statistician, who was
blind to treatment assignment, using IBM® SPSS® Statis-
tics Version 19 on a cleaned and locked database.
All analyses were conducted in accordance with the
International Conference on Harmonization E9 statistical
principles (International Conference on Harmonization,
[10]. Assuming a correlation of post-treatment scores
with baseline measurements of 0.7 and an effect of the
dosage such that experimental (usual treatment and
NAC) group differs from controls (usual treatment and
placebo) by 0.75 standard deviations, power was main-
tained above 90% with 75 subjects in each group. Differ-
ences in the two groups in baseline demographic and
clinical characteristics (week eight at randomization)
were examined using independent samples t-tests and
chi-square analysis (c2). These inferential statistics were
also used to compare participants who were included/
excluded from the maintenance phase of the trial and
who completed/discontinued the intervention.
Fisher’s exact test was used to determine differences
between the two groups with respect to the frequency of
interventions for mood episodes. Kaplan Meier estimates
and the Mantel-Cox log-rank test (c2) were used to eval-
uate differences in time to intervention for a mood epi-
sode between the NAC and placebo groups (primary
outcome). Time to depressive episode was also analyzed
using these techniques (secondary outcome).
The analyses of continuous secondary outcome mea-
sures involved the use of a likelihood based mixed-
effects model repeated measures approach (MMRM).
The MMRM model included the fixed, categorical
effects of group, visit, and group-by-visit interaction.
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The MMRM includes all available data at each time
point [28] and is the favored approach for analysis of
data from clinical trials in psychiatry [29]. The Toeplitiz
covariance structure was used to model the relations
between observations on different occasions. Planned
comparisons using MMRM were conducted to examine
group differences in mean change on the outcome mea-
sures from baseline (week 8) to endpoint (week 32). All
tests of treatment effects were conducted using a two-
sided alpha level of 0.05.
Results
Sample characteristics
One hundred and forty nine individuals meeting DSM-IV-
TR criteria for bipolar disorder on a structured clinical
interview (MINI-plus) were included in the analysis (see
Figure 1). The majority of participants were women, with
an average age of 45.8 years (SD = 11.4). Most had bipolar
I disorder and the mean duration of time since diagnosis
was 10.0 years (SD= 9.4). Prior suicidality was prevalent in
the cohort, and tobacco and alcohol use was also com-
mon, but use of other substances of abuse was infrequent.
Baseline characteristics
The two treatment groups were similar on most demo-
graphic (see Table 1), clinical and functioning measures
(see Table 2) with the exception that there were signifi-
cantly more women in the NAC group compared to pla-
cebo, c2 (1) = 8.85, P = 0.003. Detailed descriptions of
the baseline characteristics and the symptom changes in
the open-label phase have been previously published [30].
Participant flow
Of the 149 participants randomized, 132 (88.6%) com-
pleted the open label phase of the study (see Figure 1).
There were 121 participants (NAC: 77.6%, n = 59 and
placebo: 84.9%, n= 62) who had at least one follow-up
assessment during the maintenance phase of the trial.
Participants who did not have data in the maintenance
phase of the trial were less likely to have a diagnosis of
bipolar I disorder (included group 74.4% (n = 90) had
bipolar I disorder versus excluded group 48.1% (n = 13)
had bipolar I disorder), c2 (1) = 7.18, P = 0.007. For the
primary outcome measure, completers of the mainte-
nance phase of the trial were delineated on the basis of
either having an event and/or completing all visits. Based
on these criteria, 67.8% (n = 101) of the participants had
complete data for the primary outcome measure for the
maintenance phase of the trial.
There were no significant differences between the two
treatment groups with respect to completion rates on the
primary outcome variable (completers NAC: 79.1%, n =
47; placebo: 87.1%, n = 54), c2 (1) = 1.21, P = 0.271.
Participants who did, and did not, have complete data for
the primary outcome, were no different with respect to a
range of demographic, diagnostic and substance use vari-
ables. For the total cohort, completers had significantly
lower scores on the LIFE-RIFT (completers M = 10.8,
SD = 3.9; non-completers M = 13.0, SD = 3.5, t(119) =
2.33, P = 0.021) and the SLICE/LIFE (completers M =
16.0, SD = 5.1; non-completers M = 18.7, SD = 4.7,
t(119) = 2.15, P = 0.033) compared to non-completers.
Time to intervention for a mood episode
Thirteen interventions for mood events occurred in each
of the two groups. There was no significant difference
between the two groups in overall event rates, Fisher’s
exact, P = 0.531. The average survival time for the NAC
group was not significantly longer in the NAC group
(199.9 days, SE=11.0, 95%, CI (178.2, 221.5)) than the
placebo group (177.5 days, SE = 8.4, 95% CI (161.0,
194.0)), log rank c2(1) = .07, P = 0.795 (see Figure 2A
Time to depressive episode
Twenty-two (37.3%) participants in the NAC and 30
(48.4%) in the placebo group had a depressive episode,
Fisher’s exact, P = 0.147. Although the average survival
time (in days) for the NAC group (M = 170.2, SE = 12.8,
95%, CI (145.1, 195.39)) was longer than for those in the
placebo group (M = 137.4, SE = 10.4, 95%, CI (117.0,
157.7)), the difference between groups was not significant,
log rank c2(1) = .91, P = .341 (see Figure 2B).
Manic episode
Nine participants had a manic episode during the main-
tenance phase: two (3.2%) in the placebo group and
seven (11.9%) in the NAC group, Fisher’s exact, P = .070.
Given the small number of manic events, survival analysis
was not conducted.
Clinical and functioning measures
No significant group-by-visit interactions were identified
in the MMRM models for all clinical, functioning, and
QoL measures (see Table 3). Both groups, however,
improved significantly over time with respect to depres-
sion (MADRS, BDRS) and functioning (SOFAS and
GAF) measures. Planned comparisons focusing on group
differences in the mean change from week 8 to endpoint
(week 32) were non-significant for all measures (see
Table 4). Further, there were no significant between
group differences on the PGI-I scale at 32 weeks (NAC
M = 2.3, SD = 1.2; placebo M= 2 .5, SD = 1.4), P = 0.451.
Subgroup analyses
The above analyses were also undertaken for the sub-
group of participants who did not respond to NAC in the
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open label phase of the trial. Non-response was defined
as a MADRS score >7 at the end of the open label phase.
The findings from these supplementary analyses did not
differ from the outcomes of the main analyses.
Discussion
Although there was a robust decrease in symptoms in
the open-label phase of the trial using 2 grams daily of
NAC, there were no significant changes in clinical,
       
 
 
 
 
 
 
 
Assessed for eligibility 
(n= 244) 
Excluded  (n=88) 
 
  Not meeting inclusion criteria 
(n= 47) 
  Refused to participate 
(n= 26) 
  Other reasons  
(n= 15) 
Completed Randomised Phase 
(n= 44) 
Discontinued intervention (n= 21) 
Reasons: 
Lost to follow-up  (n= 2) 
Adverse Events (n= 1) 
Withdrew consent (n= 10) 
Non-adherence (n= 8) 
Completed Open Label Phase 
  (n= 65) 
Discontinued intervention (n= 11) 
Reasons: 
Lost to follow-up  (n= 3) 
Adverse Events (n= 3) 
Withdrew consent (n= 4) 
Non-adherence (n= 1) 
Allocated to A (n= 79) 
  Received allocated intervention 
  (n= 79) 
  Excluded from analysis (no post 
  baseline data)  (n= 3) 
 
Analysed (n= 76) 
Completed Open Label Phase 
  (n= 67) 
Discontinued intervention (n= 6) 
Reasons: 
Adverse Events (n= 1) 
Withdrew consent (n= 3) 
Non-adherence (n= 2) 
Allocated to B (n= 77) 
  Received allocated intervention 
  (n= 77) 
  Excluded from analysis (no post 
  baseline data)  (n= 4) 
 
Analysed (n= 73) 
Completed Randomised Phase 
(n= 49) 
Discontinued intervention (n= 18) 
Reasons: 
Lost to follow-up  (n= 2) 
Withdrew consent (n= 12) 
Non-adherence (n= 4) 
Allocation 
Randomised 
Open -Label 
Enrolled 
(n= 156) 
a
 Completion on primary outcome was defined as either completing all assessments up to and including the week 32 
assessment and/or having an intervention for a mood event. 
Figure 1 Consort flowchart for primary and secondary outcome measures.
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Table 1 Descriptive statistics depicting the differences between groups NAC and placebo on demographic and illness
characteristics.
Characteristics Descriptive statistic Total sample
n = 149
NAC
n = 76
Placebo
n = 73
Test statistic Value df P
Age M(SD) 45.8 (11.4) 47.1 (10.9) 44.4 (11.8) t-test 1.46 147 .146
Gender %Female % (n) 67.8 (101) 78.9 (60) 56.2 (41) c2 8.85 1 .003
Diagnosisa
Bipolar I disorder % (n) 69.6 (103) 73.7 (56) 65.3 (47) c2 1.24 1 .266
Bipolar II disorder % (n) 29.7 (44) 25.0 (19) 34.7 (25)
Bipolar NOS % (n) 1 (0.7) 1.3 (1) 0.0 (0)
Suicidality %Yes % (n) 70.9 (105) 69.7 (53) 72.2. (52) c2 0.11 1 .739
Age of first symptoms M(SD) 22.0 (10.6) 22.2 (11.8) 21.9 (9.2) t-test 0.17 138 .867
Age of diagnosis M(SD) 35.9 (11.6) 37.4 (12.0) 34.4 (11.2) t-test 1.58 141 .115
Duration of illness since diagnosis (years)b M(SD) 10.0 (9.4) 9.6 (9.3) 10.5 (9.6) t-test -0.74 141 .462
Mdn 7.0 6.0 7.5
Number of psychiatric hospitalisationsc M(SD) 3.0 (4.4) 3.2 (5.3) 2.8 (3.3) t-test -0.31 141 .759
Mdn 1.0 2.0 1.0
Number of manic episodes >10 % (n) 53.5 (76) 54.8 (40) 52.2 (36) c2 0.10 1 .754
Number of depressive episodes >10 % (n) 78.3 (112) 80.8 (59) 75.7 (53) c2 0.55 1 .459
Smoker %Yes b % (n) 37.1 (49) 30.8 (20) 43.3 (29) c2 2.21 1 .137
Alcohol use %Yes b % (n) 47.0 (62) 47.7 (31) 46.3 (31) c2 0.03 1 .870
Alcohol dependence/abuse b % (n) 14.2 (21) 14.5 (11) 13.9 (10) c2 0.01 1 .919
Substance use %Yes b % (n) 3.0 (4) 4.6 (3) 1.5 (1) c2 1.10 1 .295
Substance dependence/abuse b % (n) 14.3 (21) 13.3 (10) 15.3 (11) c2 0.11 1 .736
aChi-square based on two categories (Bipolar I disorder versus other) due to small cell sizes;
b These substances use variables related to status at entry to the maintenance phase of the trial (Week 8). c Inferential statistics based on logarithmic
transformed data (plus constant) because of extreme positive skewness. Untransformed descriptive statistics are reported.
Table 2 Differences between groups NAC and placebo on scores at Week 8 (at randomization) in terms of symptoms
and functioning.
Characteristics Descriptive statistic Total sample
n = 149
NAC
n = 76
Placebo
n = 7 3
Test statistic Value df P
Symptoms
YMRSa M(SD) 1.5 (2.1) 1.7 (2.4) 1.4 (1.9) t-test 0.37 130 .716
MADRSb M(SD) 12.6 (9.8) 13.1 (9.72) 12.2 (9.9) t-test 0.47 130 .638
BDRSa M(SD) 10.7 (9.1) 11.3 (8.5) 10.1 (9.7) t-test 1.20 130 .233
CGI-BP Severity
Depressiona M(SD) 2.8 (1.2) 2.9 (1.2) 2.8 (1.2) t-test 0.49 129 .625
Maniaa M(SD) 1.3 (0.7) 1.4 (0.7) 1.3 (0.6) t-test 0.17 129 .620
Overalla M(SD) 2.9 (1.2) 2.9 (1.2) 2.8 (1.2) t-test 0.29 128 .771
CGI-BP Improvement
Depressiona M(SD) 2.5 (1.2) 2.5 (1.1) 2.6 (1.3) t-test -0.17 129 .864
Maniaa M(SD) 3.8 (0.7) 3.8 (0.7) 3.9 (0.7) t-test -0.63 130 .533
Overalla M(SD) 2.6 (1.2) 2.6 (1.2) 2.7 (1.3) t-test -0.30 129 .767
Functioning
GAF M(SD) 72.2 (13.7) 71.1 (13.3) 73.3 (14.1) t-test -0.92 129 .360
SOFAS M(SD) 72.1 (13.6) 71.5 (13.0) 72.6 (14.1) t-test -0.46 129 .649
LIFE-RIFT M(SD) 11.2 (3.8) 11.5 (3.9) 10.9 (3.8) t-test 0.83 130 .410
SLICE-LIFE M(SD) 16.5 (5.2) 16.6 (5.3) 16.5 (5.0) t-test 0.17 130 .866
Q-LES-Q M(SD) 53.4 (10.8) 52.5 (10.6) 54.3 (11.0) t-test -0.98 130 .325
YMRS, Young Mania Rating Scale; MADRS, Montgomery-Asberg Depression Rating Scale; BDRS, Bipolar Depression Rating Scale; CGI-BP Clinical Global Impressions -
Bipolar Disorder; GAF, Global Assessment of Functioning; SOFAS, Social and Occupational Assessment Scale; Q-LES-Q, Quality of Life Enjoyment and Satisfaction
Questionnaire. aInferential statistics based on logarthmic transformed data (plus constant) because of extreme positive skewness. Untransformed descriptive statistics are
reported; bInferential statistics based on square root transformed data (plus constant) because of positive skewness. Untransformed descriptive statistics are reported.
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functioning and QoL measures in the maintenance
phase (see Figure 3 for the changes in mean estimates
for the BDRS over both the open-label and maintenance
phase of the trial). The improvements in depressive
symptoms reached a plateau in the open-label phase
and symptoms changed little from this very low base in
the randomized phase, such that between group differ-
ences did not emerge.
These results are not concordant with our previous
data examining NAC in bipolar disorder [31]. In a 24-
week double blind placebo controlled trial (n = 75)
adjunctive NAC was trialled in participants with either
bipolar I or II disorder [32]. In this study NAC signifi-
cantly improved clinical outcomes, particularly depres-
sion, quality of life and measures of functioning, with
large effect sizes in almost all domains. In that trial,
between group differences at endpoint were no longer
evident four weeks after treatment discontinuation. In
addition, benefits of NAC in other psychiatric disorders,
including a large clinical trial of schizophrenia [8], and
small scale clinical papers in obsessive-compulsive disor-
der [33] and compulsive disorders [9,33,34], pathological
gambling [35] and cocaine dependence [36] have been
reported.
NAC reverses models of glutathione depletion, increas-
ing peripheral [37] and brain glutathione [38]. There
appears to be reduced neurogenesis in mood disorders,
and antidepressants and mood stabilizers enhance neuro-
genesis [39]. It is noteworthy in this regard that NAC
enhances neurogenesis of neuronal stem cells. NAC pro-
motes neuronal survival after injury and has anti-inflam-
matory effects. In the forced swim test, NAC results in a
significant decrease in immobility. A neuroprotective effect
of NAC has been suggested by effects in a variety of neu-
rodegenerative disease models and lastly NAC appears to
B
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Figure 2 Survival time depicting time to intervention for mood
episode (A) and time to depressive episode (B).
Table 3 Tests of fixed effects in MMRM for measures of psychopathology and functioning.
Effect F test df P value F test df P value
Symptoms
YMRS † MADRS Total Score†
Group 2.04 1, 113.4 .156 Group 0.26 1, 121.7 .610
Time 1.45 6, 285.4 .197 Time 3.15 6, 240.6 .005
Group by time 0.99 6, 285.4 .432 Group by time 0.44 6, 240.6 .855
BDRS †
Group 0.27 1, 124.8 .604
Time 3.83 6, 245.2 .001
Group by time 0.49 6, 245.2 .813
CGI-BP Severity Depression † CGI-BP Improvement Depression †
Group 0.03 1, 126.0 .863 Group 0.14 1, 123.6 .709
Time 1.03 6, 197.4 .405 Time 2.43 6, 341.8 .026
Group by time 0.60 6, 197.4 .731 Group by time 0.54 6, 341.8 .777
CGI-BP Severity Mania † CGI-BP Improvement Mania†
Group 0.01 1, 116.0 .935 Group 0.05 1, 124.3 .822
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Table 3 Tests of fixed effects in MMRM for measures of psychopathology and functioning. (Continued)
Time 0.38 6, 247.2 .893 Time 1.99 6, 303.2 .066
Group by time 0.75 6, 247.2 .614 Group by time 1.32 6, 303.2 .248
CGI-BP Severity Overall † CGI-BP Improvement Overall†
Group 0.15 1, 122.7 .704 Group 0.05 1, 125.3 .828
Time 1.31 6, 201.0 .255 Time 3.10 6, 335.6 .006
Group by time 0.47 6, 201.0 .829 Group by time 0.38 6, 335.6 .893
Functioning
GAF SOFAS
Group 1.60 1, 121.9 .209 Group 0.46 1, 121.7 .500
Time 2.90 6, 252.9 .010 Time 4.43 6, 311.8 <.001
Group by time 0.75 6, 252.9 .609 Group by time 0.95 6, 311.8 .460
LIFE-RIFT SLICE-LIFE
Group 0.95 1, 121.4 .332 Group 0.12 1, 119.8 .732
Time 1.09 6, 242.0 .370 Time 0.86 6, 275.5 .525
Group by time 0.52 6, 242.0 .794 Group by time 0.62 6, 275.5 .714
QLESQ
Group 0.53 1, 123.2 .466
Time 1.99 6, 265.4 .067
Group by time 0.16 6, 265.4 .987
YMRS, Young Mania Rating Scale; MADRS, Montgomery-Asberg Depression Rating Scale; BDRS, Bipolar Depression Rating Scale; CGI-BP Clinical Global Impressions
- Bipolar Disorder; GAF, Global Assessment of Functioning; SOFAS, Social and Occupational Assessment Scale; LIFE-RIFT, Range of Impaired Functioning Tool;
SLICE-LIFE, Streamed Longitudinal Interval Clinical Evaluation of the Longitudinal Interview Follow-Up Evaluation; Q-LES-Q, Quality of Life Enjoyment and
Satisfaction Questionnaire. † Inferential statistics based on logarithmic transformed data (plus constant) because of extreme positive skewness.
Table 4 Secondary efficacy end points over the 32 weeks.
Change from Week 8 to Week 32
Characteristics NAC Placebo tb df P
M (SE)a M (SE)
Symptoms
YMRS† 0.1 (0.4) 0.4 (0.4) -0.68 129.7 .500
MADRS†† 0.6 (1.5) 1.5 (1.5) -0.42 141.3 .679
BDRS† 1.4 (1.4) 0.7 (1.3) 0.35 139.0 .726
CGI-BP - Severity†
Depression -0.1 (0.2) -0.3 (0.2) 0.5 186.5 .615
Mania 0.1 (0.1) -0.1 (0.1) 0.22 160.7 .826
Overall 0.1 (0.2) -0.2 (0.2) 0.46 167.4 .646
CGI-BP - Improvement
Depression 0.1 (0.3) 0.2 (0.3) -0.24 105.6 .814
Mania C -0.2 (0.2) 0.0 (0.2) -1.23 67.6 .222
Overall 0.1 (0.3) 0.3 (0.3) -0.39 93.4 .695
Functioning
GAF -3.2 (1.8) -4.4 (1.7) 0.54 136.7 .593
SOFAS -3.6 (1.8) -4.5 (1.7) 0.36 165.0 .719
LIFE-RIFT 0.5 (0.5) 1.1 (0.5) -0.76 100.5 .449
SLICE-LIFE 0.2 (0.8) 1.2 (0.8) -0.89 107.4 .376
QLESQ -1.7 (1.8) -2.0 (1.7) 0.14 120.5 .890
YMRS, Young Mania Rating Scale; MADRS, Montgomery-Asberg Depression Rating Scale; BDRS, Bipolar Depression Rating Scale; CGI-BP Clinical Global Impressions
- Bipolar Disorder; GAF, Global Assessment of Functioning ; SOFAS, Social and Occupational Assessment Scale; LIFE-RIFT, Range of Impaired Functioning Tool;
SLICE-LIFE, Streamed Longitudinal Interval Clinical Evaluation for the Longitudinal Interview Follow-Up Evaluation; Q-LES-Q, Quality of Life Enjoyment and
Satisfaction Questionnaire. aLeast squares mean (standard error) derived from MMRM; b Planned comparisons from the MMRM testing the difference in Week 8
to Week 32 change between A and B groups; c Note that the estimate here is derived without investigator in the model, will have to re-run; † Inferential
statistics based on logarithmic transformed data (plus constant) because of extreme positive skewness. Untransformed descriptive statistics are reported; ††
Inferential statistics based on square root transformation because of positive skewness. Untransformed descriptive statistics are reported.
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reverse mitochondrial dysfunction, which is concordant
with the emerging literature on the role of mitochondria
in bipolar disorder.
The characteristics of this study need to be mentioned
in order to contextualize these results. The multi-center,
randomized, placebo controlled design provides an
appropriate forum for evaluation of efficacy in the conti-
nuation phase. The sample size, while ample for the sec-
ondary outcome measures, was marginal for the ability to
evaluate recurrence, which only occurred in a subset of
participants. A larger sample size and a longer length of
the randomized phase, concordant with similar recent
designs, would have increased the signal to noise ratio in
this regard. Other studies have used responder analysis
to determine benefits during the maintenance phase;
these trials only include those who respond in the open-
label phase for analysis of the maintenance phase. While
not an a priori analysis, this was investigated in the cur-
rent study with no change in the outcomes reported
(data not shown). The absence of significant restrictions
on comorbid diagnosis reflects the extent of comorbidity
in the disorder; similarly, the absence of restrictions
regarding concomitant therapy also enhances the gener-
alizability of the data, as does the inclusion of bipolar I-,
II- and NOS - disorder participants.
Conclusions
In conclusion, there was a substantial decrease in symp-
toms during the eight-week open label phase. During the
subsequent double blind phase, there was a very low
baseline reflecting improvement across all symptomatic
measures, and this did not change significantly in either
group. As a consequence, between group differences
could not emerge on recurrence, clinical functioning and
QoL measures. This lack of a workable symptomatic sub-
strate for the emergence of a signal in the double blind
phase suggests that this study could possibly be seen as a
failed rather than negative study. As such, the formal
maintenance efficacy of NAC in bipolar disorder remains
an open question.
Additional material
Additional file 1: Timetable for assessments during the open label
and maintenance phases of the trial. This table provides an outline of
the trial schedule and timing of rating scale and associated trial interview
delivery.
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